Share on StockTwits

Portola Pharmaceuticals (NASDAQ:PTLA) is scheduled to release its Q114 earnings data on Monday, May 12th. Analysts expect Portola Pharmaceuticals to post earnings of ($0.72) per share and revenue of $1.81 million for the quarter.

Portola Pharmaceuticals (NASDAQ:PTLA) last released its earnings data on Thursday, February 27th. The company reported ($0.63) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.57) by $0.06. The company had revenue of $2.10 million for the quarter, compared to the consensus estimate of $2.17 million. On average, analysts expect Portola Pharmaceuticals to post $-3.52 EPS for the current fiscal year and $-3.68 EPS for the next fiscal year.

Portola Pharmaceuticals (NASDAQ:PTLA) opened at 23.10 on Friday. Portola Pharmaceuticals has a 1-year low of $14.75 and a 1-year high of $30.95. The stock has a 50-day moving average of $24.47 and a 200-day moving average of $25.23. The company’s market cap is $947.8 million. Portola Pharmaceuticals also saw a significant growth in short interest in April. As of April 15th, there was short interest totalling 1,322,151 shares, a growth of 41.8% from the March 31st total of 932,507 shares. Approximately 4.5% of the shares of the stock are short sold. Based on an average trading volume of 378,684 shares, the short-interest ratio is presently 3.5 days.

In other Portola Pharmaceuticals news, CFO Mardi Dier unloaded 5,000 shares of the company’s stock on the open market in a transaction that occurred on Friday, April 25th. The shares were sold at an average price of $24.14, for a total value of $120,700.00. Following the transaction, the chief financial officer now directly owns 24,824 shares of the company’s stock, valued at approximately $599,251. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Portola Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapeutics in the areas of thrombosis, other hematologic disorders and inflammation for patients who has limited or no approved treatment options.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.